AstraZeneca PLC
NYSE:AZN · New York Stock Exchange
-$3.04 today
Vol 1.52M · Avg 1.96M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $7.6B |
| Short-term Investments | $115.0M |
| Receivables | $14.1B |
| Inventory | $6.6B |
| Other Current | $1.3B |
| Total Current Assets | $29.6B |
| PP&E (Net) | $14.9B |
| Goodwill | $21.2B |
| Intangible Assets | $36.9B |
| Long-term Investments | $4.2B |
| Tax Assets | $5.6B |
| Other Non-current | $1.5B |
| Total Non-current Assets | $84.4B |
| Total Assets | $114.0B |
Analysis
Selected assets total $114.0B for Latest. The largest visible component is Intangible Assets at $36.9B, about 32.4% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $5.7B +4.1% | $5.5B -6.0% | $5.8B -5.3% | $6.2B -2.6% | $6.3B | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $30.0M -18.9% | $37.0M +85.0% | $20.0M -74.0% | $77.0M +11.6% | $69.0M | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $15.2B +35.1% | $11.2B +33.6% | $8.4B -8.5% | $9.2B +13.0% | $8.1B | $533.8M | $399.4M | -$1.7B |
| Inventory | $6.6B +24.0% | $5.3B -2.5% | $5.4B +15.4% | $4.7B -47.7% | $9.0B | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $1.2B -38.9% | $2.0B -45.5% | $3.7B +231.5% | $1.1B -7.3% | $1.2B | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $28.7B +11.2% | $25.8B +3.1% | $25.1B +10.9% | $22.6B -13.9% | $26.2B | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $14.7B +26.2% | $11.6B +10.9% | $10.5B +11.1% | $9.4B -7.1% | $10.2B | $1.2B | $1.5B | $687.8M |
| Goodwill | $21.2B +1.0% | $21.0B +4.9% | $20.0B +1.2% | $19.8B -0.9% | $20.0B | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $37.8B +1.8% | $37.2B -2.4% | $38.1B -3.1% | $39.3B -7.3% | $42.4B | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $2.5B | $0 -100.0% | $1.8B | $0 | $0 | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $0 -100.0% | $5.3B | $0 -100.0% | $3.3B -24.6% | $4.3B | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $9.0B +200.0% | $3.0B -46.7% | $5.6B +175.4% | $2.1B -8.2% | $2.2B | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $85.4B +9.1% | $78.2B +2.8% | $76.1B +2.9% | $73.9B -6.6% | $79.1B | -$15.3B | $14.8B | $11.3B |
| Total Assets | $114.1B +9.6% | $104.0B +2.9% | $101.1B +4.8% | $96.5B -8.4% | $105.4B | $13.3B | $11.9B | $10.6B |
| Account Payables | $25.3B +594.5% | $3.6B +11.4% | $3.3B +28.1% | $2.5B -9.7% | $2.8B | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $3.2B +47.7% | $2.2B -58.0% | $5.1B -1.8% | $5.2B +233.4% | $1.6B | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $0 -100.0% | $1.8B -13.0% | $2.1B +52.2% | $1.4B -1.1% | $1.4B | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $0 | $0 | $0 | $0 | $0 | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $686.0M -96.0% | $17.3B +182.3% | $6.1B -59.1% | $15.0B +0.4% | $14.9B | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $30.6B +9.9% | $27.9B -8.8% | $30.5B +16.2% | $26.3B +16.4% | $22.6B | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $24.7B -6.8% | $26.5B +18.5% | $22.4B -2.6% | $23.0B -18.4% | $28.1B | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $3.5B +6.1% | $3.3B +10561.3% | $31.0M -98.9% | $2.9B -52.6% | $6.2B | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $0 | $0 -100.0% | $7.0M -50.0% | $14.0M -46.2% | $26.0M | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | $5.1B +16.6% | $4.4B -46.3% | $8.2B +25.7% | $6.5B -22.5% | $8.4B | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $34.7B -1.6% | $35.3B +12.4% | $31.4B -5.2% | $33.1B -23.8% | $43.5B | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $65.4B +3.5% | $63.2B +2.0% | $62.0B +4.3% | $59.4B -10.1% | $66.1B | $14.7B | $3.7B | $9.6B |
| Common Stock | $388.0M +0.0% | $388.0M +0.0% | $388.0M +0.3% | $387.0M +0.0% | $387.0M | $651.4M | $517.0M | $382.6M |
| Retained Earnings | $11.0B +247.2% | $3.2B -30.0% | $4.5B +886.8% | -$574.0M -133.6% | $1.7B | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | $0 | $0 | $0 | $0 | $0 | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $2.0B +10.0% | $1.9B +197.9% | -$1.9B -199.1% | $1.9B +1.3% | $1.9B | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $52.0M -38.8% | $85.0M +269.6% | $23.0M +9.5% | $21.0M +10.5% | $19.0M | $1.4B | $337.8M | $931.4M |
| Total Equity | $48.7B +19.2% | $40.9B +4.4% | $39.2B +5.7% | $37.1B -5.7% | $39.3B | $9.1B | $7.7B | $3.3B |
| Total Debt | $29.7B -1.4% | $30.1B +5.2% | $28.6B -1.8% | $29.1B -5.0% | $30.7B | $724.2M | $410.6M | $399.4M |
| Net Debt | $24.0B -2.6% | $24.6B +8.1% | $22.8B -0.8% | $23.0B -5.7% | $24.4B | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Eli Lilly and Company
NYSE:LLY
$1.04T
Johnson & Johnson
NYSE:JNJ
$551.91B
AbbVie Inc.
NYSE:ABBV
$382.35B
Roche Holding AG
RHHBY
$320.95B
Merck & Co., Inc.
NYSE:MRK
$281.78B
Novartis AG
NYSE:NVS
$281.47B
Amgen Inc.
NASDAQ:AMGN
$180.77B
Gilead Sciences, Inc.
NASDAQ:GILD
$152.53B
Pfizer Inc.
NYSE:PFE
$143.80B
Bristol-Myers Squibb Company
NYSE:BMY
$109.97B
GSK plc
NYSE:GSK
$101.97B
Sanofi
NASDAQ:SNY
$101.52B
SEC Filings
Recent regulatory filings
No filings found.
How much cash does AZN have?
AstraZeneca PLC (AZN) reported $5.71B in cash and equivalents in fiscal 2025.
How much debt does AZN carry?
AstraZeneca PLC (AZN) reported $29.70B of total debt, with net debt of $23.99B.
Explore More
Continue the stock analysis
Jump to another research area for this company.